The genetic basis of platelet responsiveness to clopidogrel; A critical review of the literature

Paul Fefer, Shlomi Matetzky*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Clopidogrel reduces ischaemic complications in a wide range of patients with coronary artery disease. However, there is much inter-individual variation in clopidogrel-induced platelet inhibition, and a substantial proportion of patients will exhibit non-responsiveness to clopidogrel. Multiple studies have demonstrated an association between the presence of genetic polymorphisms associated with suboptimal clopidogrel-active metabolite generation, decreased platelet respon- siveness, and adverse clinical outcomes. However, it is not clear to what extent the genetic polymorphisms account for the observed variability in response to clopidogrel. In this review we provide a critical summary of the available evidence linking genetic factors with response to clopidogrel, and discuss the clinical implications of this association.

Original languageEnglish
Pages (from-to)203-210
Number of pages8
JournalThrombosis and Haemostasis
Volume106
Issue number2
DOIs
StatePublished - 2011

Keywords

  • Antiplatelet agents
  • Platelet pharmacology
  • Polymorphisms

Fingerprint

Dive into the research topics of 'The genetic basis of platelet responsiveness to clopidogrel; A critical review of the literature'. Together they form a unique fingerprint.

Cite this